Effect of Lactulose on Patients with Inflammatory Bowel Disease
Author Information
Author(s): Anne Hafer, Sigrid Krämer, Swantje Duncker, Martin Krüger, Michael P. Manns, Stephan C. Bischoff
Primary Institution: Medical School of Hannover
Hypothesis
The study aimed to investigate the clinical and histological efficacy of lactulose in patients with inflammatory bowel disease (IBD).
Conclusion
Oral lactulose has no beneficial effects on clinical activity, endoscopic score, or immunohistochemical parameters in IBD patients, although it may improve quality of life in ulcerative colitis patients.
Supporting Evidence
- 14 patients with ulcerative colitis and 17 with Crohn's disease were enrolled.
- No significant improvement in clinical activity index or endoscopic score was observed.
- Quality of life improved significantly in UC patients receiving lactulose compared to controls.
Takeaway
This study looked at whether a sugar called lactulose helps people with gut problems called inflammatory bowel disease, and it found that it doesn't really help with their symptoms, but it might make some feel a bit happier.
Methodology
Patients were treated with standard medication alone or combined with 10 g lactulose daily for 4 months, with various clinical and laboratory parameters assessed.
Potential Biases
The lack of a placebo group raises concerns about potential placebo effects influencing the results.
Limitations
The study was a pilot study with a small sample size and not placebo-controlled, which may affect the reliability of the results.
Participant Demographics
The study included 31 patients, with 14 having ulcerative colitis and 17 having Crohn's disease, most in a clinically active state.
Statistical Information
P-Value
0.04
Statistical Significance
p = 0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website